Is Milestone Pharmaceuticals Inc (NASDAQ: MIST) Stock On Course For Another Boom Or Bust?

During the last session, Milestone Pharmaceuticals Inc (NASDAQ:MIST)’s traded shares were 0.43 million, with the beta value of the company hitting 1.73. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday loss of -0.69% or -$0.01. The 52-week high for the MIST share is $3.52, that puts it down -144.44 from that peak though still a striking 22.22% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $76.71M, and the average intraday trading volume over the past 10 days was 0.3 million shares, and the average trade volume was 144.70K shares over the past three months.

Milestone Pharmaceuticals Inc (MIST) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. MIST has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Milestone Pharmaceuticals Inc (NASDAQ:MIST) trade information

The stock plummet -0.69% in intraday trading to $1.44, hitting a weekly high. The stock’s 5-day price performance is 0.00%, and it has moved by -4.00% in 30 days. Based on these gigs, the overall price performance for the year is -48.57%. The short interest in Milestone Pharmaceuticals Inc (NASDAQ:MIST) is 0.45 million shares and it means that shorts have 4.79 day(s) to cover.

The consensus price target of analysts on Wall Street is $10, which implies an increase of 85.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $10 respectively. As a result, MIST is trading at a discount of -594.44% off the target high and -594.44% off the low.

Milestone Pharmaceuticals Inc (MIST) estimates and forecasts

Statistics show that Milestone Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Milestone Pharmaceuticals Inc (MIST) shares have gone down -14.79% during the last six months, with a year-to-date growth rate more than the industry average at 54.68% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 54.30% this quarter and then jump 46.90% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -7.22%. While earnings are projected to return 52.70% in 2024.

MIST Dividends

Milestone Pharmaceuticals Inc is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Milestone Pharmaceuticals Inc (NASDAQ:MIST)’s Major holders

Milestone Pharmaceuticals Inc insiders own 0.69% of total outstanding shares while institutional holders control 56.91%, with the float percentage being 57.31%. BLACKROCK INC. is the largest shareholder of the company, while 46.0 institutions own stock in it. As of 2024-06-30, the company held over 4.97 million shares (or 9.9119% of all shares), a total value of $6.56 million in shares.

The next largest institutional holding, with 3.26 million shares, is of RTW INVESTMENTS, LP’s that is approximately 6.4921% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.3 million.